Key Points
- Chairman Adam Craig sold 47,436 X4 Pharmaceuticals shares at an average price of $4.44, generating approximately $210,616. The sale reduced his ownership by 12.61% to 328,651 shares.
- X4 reported quarterly revenue of $8.81 million and an adjusted loss of $0.13 per share, beating analyst expectations for $2.42 million in revenue and a $0.18 per-share loss.
- Analysts maintain a consensus “Moderate Buy” rating with an average price target of $11.25, well above the stock’s recent price near $4.29; institutional investors own 72.03% of the company.
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) President John Volpone sold 24,576 shares of X4 Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $109,117.44. Following the completion of the transaction, the president directly owned 265,305 shares of the company's stock, valued at approximately $1,177,954.20. This represents a 8.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
X4 Pharmaceuticals Stock Performance
Shares of XFOR stock opened at $4.29 on Friday. The company has a market capitalization of $425.35 million, a price-to-earnings ratio of -3.57 and a beta of 0.37. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18. X4 Pharmaceuticals, Inc. has a one year low of $2.45 and a one year high of $4.83. The company's 50-day moving average is $4.04 and its 200 day moving average is $3.96.
X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. The business had revenue of $8.81 million during the quarter, compared to analysts' expectations of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 64.95%. Sell-side analysts expect that X4 Pharmaceuticals, Inc. will post -0.71 EPS for the current fiscal year.
Analyst Ratings Changes
Several analysts have commented on XFOR shares. Wells Fargo & Company assumed coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They set an "overweight" rating and a $11.00 target price on the stock. Leerink Partners began coverage on X4 Pharmaceuticals in a report on Tuesday, June 2nd. They set an "outperform" rating and a $12.00 price target on the stock. Finally, Weiss Ratings downgraded X4 Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $11.25.
View Our Latest Report on X4 Pharmaceuticals
Institutional Investors Weigh In On X4 Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in the stock. Pettinga Financial Advisors LLC purchased a new stake in X4 Pharmaceuticals during the 2nd quarter valued at $47,000. Indivisible Partners purchased a new stake in X4 Pharmaceuticals during the fourth quarter valued at $40,000. SummitTX Capital L.P. bought a new position in X4 Pharmaceuticals in the first quarter valued at about $46,000. Squarepoint Ops LLC purchased a new position in X4 Pharmaceuticals in the fourth quarter worth about $50,000. Finally, Two Sigma Investments LP bought a new stake in shares of X4 Pharmaceuticals during the 3rd quarter valued at about $47,000. Institutional investors own 72.03% of the company's stock.
About X4 Pharmaceuticals
(
Get Free Report)
X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company's lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.
Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström's macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
